Trial
NCT06488911
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Intercept Pharmaceuticals
Collaborators
—
Condition
Primary Biliary Cholangitis
Intervention
FDC tablet (OCA 5 mg + BZF 400 mg SR)
Why stopped
Intercept made a business decision to terminate the study based on FDA's request for voluntary withdrawal of Ocaliva and the issuance of clinical hold on studies under US IND involving OCA.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-08